Things are not looking good for big pharma. Major blockbuster drugs are under attack, public scrutiny is growing, price pressure is rising, patents are expiring, and generic competition is increasing. Meanwhile, pipelines are in the same poor state as ever, filled with me-too, potential blockbuster candidates, but precious few novel medicines.
